Cardiocore Consortium Wins 10-Year, $20B National Institutes of Health Contract
09.July.2012; Washington, DC-Cardiocore, a premier centralized cardiac testing laboratory and technology provider, announced today that its consortium has been awarded the coveted Chief Information Officer-Solutions and Partners 3 (CIO-SP3) Government Wide Acquisition Contract (GWAC). This contract, sponsored by the National Institutes of Health (NIH), is valued at $20 billion over a 10-year term.
Led by Creative Information Technology (CITI), Cardiocore’s team also includes ICON Medical Imaging and Zimmerman Associates (ZAI). These organizations are joined through a Contractor Team Agreement (CTA). In total, the NIH’s CIO-SP3 indefinite delivery/indefinite quantity (ID/IQ) program comprises approximately 50 contractors, serving a wide range of government agencies, with particular focus on Biomedical Research, Health Sciences, and Healthcare work orders.
"We are very pleased that our team has been selected by the NIH for this landmark CIO-SP3 award," said Scott Satin, Cardiocore’s Vice President of Marketing. "We look forward to expanding our NIH and other government-sponsored services in the decade ahead, and we are delighted to be part of such a well-qualified, well-experienced coalition."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
